# PRODUCT INFORMATION



## **AZD 8835**

Item No. 29166

CAS Registry No.: 1620576-64-8

Formal Name: 1-[4-[5-[5-amino-6-[5-(1,1-dimethylethyl)-

1,3,4-oxadiazol-2-yl]-2-pyrazinyl]-1-ethyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl]-3-


hydroxy-1-propanone

MF:  $C_{22}H_{31}N_9O_3$ FW: 469.5 **Purity:** 

UV/Vis.:  $\lambda_{max}$ : 235, 289, 378 nm Supplied as: A crystalline solid

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



### **Laboratory Procedures**

AZD 8835 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 8835 in the solvent of choice, which should be purged with an inert gas. AZD 8835 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of AZD 8835 in ethanol is approximately 2 mg/ml and approximately 16 mg/ml in DMSO and DMF.

AZD 8835 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AZD 8835 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. AZD 8835 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

#### Description

AZD 8835 is an inhibitor of PI3K $\alpha$  and PI3K $\delta$  (IC<sub>50</sub>s = 6.2 and 5.7 nM, respectively).<sup>1</sup> It is selective for PI3K $\alpha$  and PI3K $\delta$  over PI3K $\beta$  and PI3K $\gamma$  (IC<sub>50</sub>s = 431 and 90 nM, respectively). AZD 8835 inhibits Akt phosphorylation in PIK3CA constitutively active mutant BT474 cells and Jeko-1 B cells that express endogenous PI3K $\delta$  (IC<sub>50</sub>s = 57 and 49 nM, respectively). In vivo, AZD 8835 (25 mg/kg) reduces tumor growth and Akt phosphorylation in a SKOV3 mouse xenograft model. It also increases the activity of CD8<sup>+</sup> effector T cells and reduces tumor growth in a C26 mouse syngeneic tumor model.<sup>2</sup>

#### References

- 1. Barlaam, B., Cosulich, S., Delouvrié, B., et al. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers. Bioorg. Med. Chem. Lett. 25(22), 5155-5162 (2015).
- 2. Carnevalli, L.S., Sinclair, C., Taylor, M.A., et al. Pl3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8<sup>+</sup> T-cell activity. J. Immunother. Cancer 6(1), 158 (2018).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/20/2022

## **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM